KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Average (2016 - 2025)

Nektar Therapeutics has reported Equity Average over the past 15 years, most recently at $87.5 million for Q4 2025.

  • Quarterly results put Equity Average at $87.5 million for Q4 2025, up 59.57% from a year ago — trailing twelve months through Dec 2025 was $87.5 million (up 59.57% YoY), and the annual figure for FY2025 was $75.3 million, down 21.47%.
  • Equity Average for Q4 2025 was $87.5 million at Nektar Therapeutics, up from $30.4 million in the prior quarter.
  • Over the last five years, Equity Average for NKTR hit a ceiling of $1.0 billion in Q1 2021 and a floor of -$5.2 million in Q2 2025.
  • Median Equity Average over the past 5 years was $198.5 million (2023), compared with a mean of $346.4 million.
  • Peak annual rise in Equity Average hit 59.57% in 2025, while the deepest fall reached 105.07% in 2025.
  • Nektar Therapeutics' Equity Average stood at $740.5 million in 2021, then tumbled by 47.41% to $389.4 million in 2022, then crashed by 62.72% to $145.2 million in 2023, then plummeted by 62.25% to $54.8 million in 2024, then soared by 59.57% to $87.5 million in 2025.
  • The last three reported values for Equity Average were $87.5 million (Q4 2025), $30.4 million (Q3 2025), and -$5.2 million (Q2 2025) per Business Quant data.